The peptide hormone prolactin (PRL) exerts a profound effect on both cellular proliferation and differentiation in a variety of tissues, but its role as an immunomodulator has not been well-defined. That PRL plays a potentially important role as a novel T and B cell cytokine has been strengthened by the observations that the PRL receptor (PRL-R), a member of the cytokine receptor superfamily, is expressed on cells of the immune system, and that some of these cells also synthesize and secrete biologically-active PRL. The long-term objective of this proposal is to understand the immunoregulatory properties of PRL. As a model system for investigating the role of PRL as a T cell cytokine, we are using the rat Nb2 T lymphoma cells which require PRL for growth. A major target of PRL stimulation in Nb2 T cells is the transcription factor, interferon regulatory factor-1 (IRF-1). In T cells, PRL stimulates the biphasic expression of IRF-1, first during G1 activation, and again over G1/S transition, where its expression is tightly linked to DNA synthesis and subsequent cell proliferation. Our recent studies have implicated the cytokine signaling molecules """"""""signal transducer and activator of transcription"""""""" or Stat, and the cell cycle-regulated transcription complex containing retinoblastoma protein (Rb) as possible PRL signaling molecules at the IRF-i promoter. Our working hypothesis is that PRL and its receptors are involved in signaling for G1 activation as well as for S phase progression in activated T cells. Both cytokine and cell cycle signaling molecules are activated at the IRF-I promoter in a biphasic manner. We further suggest that the transcription factor IRF-1 is a nuclear mediator of PRL action during these distinct phases of the T cell cycle. The proposed studies aim to elucidate how cytokine signal transduction may be integrated with cell cycle control signals to regulate IRF-1 expression, and how IRF-1 may be important for T cell activation and proliferation. Studies are proposed to: 1) Characterize the biphasic PRL response at the IRF-1 promoter during G1 versus S phase, and to elucidate how Stat and Rb proteins participate in these responses. Mutational analysis of promoter elements coupled with studies of protein!DNA interactions will help to identify cis-acting elements and the transacting factors important for PRL stimulation of the IRF-1 gene; and 2) Investigate IRF-1 function and PRL action in T cells. CD8+ T cells from thymocytes and splenocytes representing different stages of development will be analyzed as potential targets of PRL immunomodulation. IRF-1 target genes will also be cloned by differential display PCR, as one way of understanding how PRL (a cytokine signal) and IRF-1 (one cytokine target) modulate T cell activation and proliferation. These studies represent a comprehensive molecular, genetic, biochemical and immunological approach to defining how cytokine signals are integrated with cell cycle signals to regulate IRF-1 gene expression in T lymphocytes. Understanding how PRL modulates the biological functions of T cells should elucidate the immunoregulatory properties of PRL, and provide new insights into neuroendocrine-immune system interactions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
2R01DK044625-04
Application #
2143934
Study Section
Immunobiology Study Section (IMB)
Project Start
1992-03-01
Project End
1999-02-28
Budget Start
1995-03-24
Budget End
1996-02-29
Support Year
4
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Book McAlexander, M; Yu-Lee, L Y (2001) Sp1 is required for prolactin activation of the interferon regulatory factor-1 gene. Mol Cell Endocrinol 184:135-41
Book McAlexander, M; Yu-Lee, L (2001) Prolactin activation of IRF-1 transcription involves changes in histone acetylation. FEBS Lett 488:91-4
Luo, G; Yu-Lee, L (2000) Stat5b inhibits NFkappaB-mediated signaling. Mol Endocrinol 14:114-23
Herrington, J; Rui, L; Luo, G et al. (1999) A functional DNA binding domain is required for growth hormone-induced nuclear accumulation of Stat5B. J Biol Chem 274:5138-45
Yu-Lee, L Y; Luo, G; Book, M L et al. (1998) Lactogenic hormone signal transduction. Biol Reprod 58:295-301
Yu-Lee, L; Luo, G; Moutoussamy, S et al. (1998) Prolactin and growth hormone signal transduction in lymphohaemopoietic cells. Cell Mol Life Sci 54:1067-75
Smit, L S; Vanderkuur, J A; Stimage, A et al. (1997) Growth hormone-induced tyrosyl phosphorylation and deoxyribonucleic acid binding activity of Stat5A and Stat5B. Endocrinology 138:3426-34
Wang, Y; O'Neal, K D; Yu-Lee, L (1997) Multiple prolactin (PRL) receptor cytoplasmic residues and Stat1 mediate PRL signaling to the interferon regulatory factor-1 promoter. Mol Endocrinol 11:1353-64
Yu-Lee, L Y (1997) Molecular actions of prolactin in the immune system. Proc Soc Exp Biol Med 215:35-52
Luo, G; Yu-Lee, L (1997) Transcriptional inhibition by Stat5. Differential activities at growth-related versus differentiation-specific promoters. J Biol Chem 272:26841-9

Showing the most recent 10 out of 19 publications